Estimates of the Burden of Group B Streptococcal Disease Worldwide for Pregnant Women, Stillbirths, and Children

Anna C. Seale; Fiorella Bianchi-Jassir; Neal Russell; Maya Kohli-Lynch; Cally J Tann; Jenny Hall; Lola Madrid; Hannah Blencowe; Simon Cousens; Carol J. Baker; Linda Bartlett; Clare Cutland; Michael G. Gravett; Paul T. Heath; Margaret Ip; Kirsty Le Doaré; Shabir A. Madhi; Craig E. Rubens; Samir K. Saha; Stephanie J. Schrag; Ajoke Sobanjo-ter Meulen; Johan Vekemans; Joy E Lawn

doi:10.1093/cid/cix664

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Our conservative estimates suggest that GBS is a leading contributor to adverse maternal and newborn outcomes, with at least 409000 (UR, 144000-573000) maternal/fetal/infant cases and 147000 (UR, 47000-273000) stillbirths and infant deaths annually. An effective GBS vaccine could reduce disease in the mother, the fetus, and the infant.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Seale et al. (2017) studied this question.

synapsesocial.com/papers/69d6b4edf174babf6cab32b8 https://doi.org/10.1093/cid/cix664

View Full Paper

Ask AI

Bookmark

Share

Estimates of the Burden of Group B Streptococcal Disease Worldwide for Pregnant Women, Stillbirths, and Children

Ask about this paper

Abstract

Discussion

Cite This Study

Estimates of the Burden of Group B Streptococcal Disease Worldwide for Pregnant Women, Stillbirths, and Children

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading